Steven Cohen Biotechnology

Point72 Asset Management, L.P.

$42.2 Billion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
CRNX Crinetics Pharmaceuticals, Inc.	$1.98B	$143 Million 0.34% of portfolio	2,788,939	Q4 2024 Added 21.22%
ARGX Argenx Se	$35.8B	$91 Million 0.22% of portfolio	147,989	Q4 2024 New
INCY Incyte Corp	$15.9B	$88.3 Million 0.21% of portfolio	1,278,369	Q4 2024 Reduced 46.04%
ASND Ascendis Pharma A/S	$8.63B	$69.3 Million 0.16% of portfolio	503,669	Q4 2024 Added 1.64%
PTCT Ptc Therapeutics, Inc.	$3.6B	$65.2 Million 0.15% of portfolio	1,443,362	Q4 2024 Added 150.64%
BCYC Bicycle Therapeutics PLC	$356M	$63.8 Million 0.15% of portfolio	4,554,900	Q4 2024 Added 406.21%
CLDX Celldex Therapeutics, Inc.	$1.06B	$63.6 Million 0.15% of portfolio	2,515,972	Q4 2024 Added 60.38%
CNTA Centessa Pharmaceuticals PLC	$1.5B	$57.4 Million 0.14% of portfolio	3,426,599	Q4 2024 Added 26.18%
XNCR Xencor Inc	$943M	$50 Million 0.12% of portfolio	2,177,081	Q4 2024 Reduced 30.23%
RARE Ultragenyx Pharmaceutical Inc.	$3.12B	$49.8 Million 0.12% of portfolio	1,182,877	Q4 2024 Added 80.96%
COGT Cogent Biosciences, Inc.	$531M	$41.7 Million 0.1% of portfolio	5,347,302	Q4 2024 Reduced 48.93%
ACAD Acadia Pharmaceuticals Inc	$3.28B	$40.9 Million 0.1% of portfolio	2,230,815	Q4 2024 New
APLS Apellis Pharmaceuticals, Inc.	$3.11B	$40.5 Million 0.1% of portfolio	1,267,958	Q4 2024 New
JANX Janux Therapeutics, Inc.	$1.55B	$33.3 Million 0.08% of portfolio	621,383	Q4 2024 Added 56.96%
VRNA Verona Pharma PLC	$3.9B	$33 Million 0.08% of portfolio	711,007	Q4 2024 New
QURE Uni Qure N.V.	$606M	$31.3 Million 0.07% of portfolio	1,771,352	Q4 2024 Added 81.33%
RCUS Arcus Biosciences, Inc.	$775M	$29.7 Million 0.07% of portfolio	1,996,279	Q4 2024 Reduced 18.09%
ANNX Annexon, Inc.	$135M	$28.9 Million 0.07% of portfolio	5,626,796	Q4 2024 Added 5.63%
SNDX Syndax Pharmaceuticals Inc	$904M	$25.3 Million 0.06% of portfolio	1,915,736	Q4 2024 Reduced 31.05%
OCUL Ocular Therapeutix, Inc	$568M	$25.1 Million 0.06% of portfolio	2,935,924	Q4 2024 Added 43.87%
AKRO Akero Therapeutics, Inc.	$2.35B	$25 Million 0.06% of portfolio	899,680	Q4 2024 Reduced 30.97%
ARQT Arcutis Biotherapeutics, Inc.	$808M	$24.4 Million 0.06% of portfolio	1,753,522	Q4 2024 Added 617.52%
DYN Dyne Therapeutics, Inc.	$715M	$21.8 Million 0.05% of portfolio	924,681	Q4 2024 Added 802.3%
OLMA Olema Pharmaceuticals, Inc.	$203M	$21.4 Million 0.05% of portfolio	3,670,826	Q4 2024 Reduced 0.45%
VCYT Veracyte, Inc.	$2.94B	$20.7 Million 0.05% of portfolio	523,162	Q4 2024 New
PCVX Vaxcyte, Inc.	$4.89B	$20.6 Million 0.05% of portfolio	251,055	Q4 2024 Reduced 30.22%
RCKT Rocket Pharmaceuticals, Inc.	$823M	$19.7 Million 0.05% of portfolio	1,569,823	Q4 2024 Added 3,163.94%
TRVI Trevi Therapeutics, Inc.	$267M	$17.7 Million 0.04% of portfolio	4,150,237	Q4 2024 New
BMRN Biomarin Pharmaceutical Inc	$12.8B	$17.5 Million 0.04% of portfolio	266,436	Q4 2024 Added 34.76%
NRIX Nurix Therapeutics, Inc.	$803M	$16.4 Million 0.04% of portfolio	872,959	Q4 2024 New
CRVS Corvus Pharmaceuticals, Inc.	$210M	$15.8 Million 0.04% of portfolio	3,030,011	Q4 2024 Reduced 45.53%
AXSM Axsome Therapeutics, Inc.	$5.54B	$15.7 Million 0.04% of portfolio	185,138	Q4 2024 Reduced 65.88%
BPMC Blueprint Medicines Corp	$5.63B	$14.5 Million 0.03% of portfolio	166,418	Q4 2024 New
IMCR Immunocore Holdings PLC	$1.31B	$11.9 Million 0.03% of portfolio	403,304	Q4 2024 New
DSGN Design Therapeutics, Inc.	$280M	$11.5 Million 0.03% of portfolio	1,856,750	Q4 2024 Added 15.99%
DNLI Denali Therapeutics Inc.	$2.9B	$11.2 Million 0.03% of portfolio	548,739	Q4 2024 Added 64.52%
JAZZ Jazz Pharmaceuticals PLC	$8.57B	$10.4 Million 0.02% of portfolio	84,151	Q4 2024 Reduced 68.69%
LIFE A Tyr Pharma Inc	$53.2M	$9.08 Million 0.02% of portfolio	4,883,197	Q4 2024 New
VERA Vera Therapeutics, Inc.	$798M	$8.21 Million 0.02% of portfolio	194,027	Q4 2024 Added 13.09%
CYTK Cytokinetics Inc	$4.81B	$7.99 Million 0.02% of portfolio	169,913	Q4 2024 Reduced 63.38%
VERV Verve Therapeutics, Inc.	$469M	$7.86 Million 0.02% of portfolio	1,394,116	Q4 2024 New
AUPH Aurinia Pharmaceuticals Inc.	$1.11B	$7.63 Million 0.02% of portfolio	849,621	Q4 2024 New
ZLAB Zai Lab LTD	$3.03B	$7.43 Million 0.02% of portfolio	283,600	Q4 2024 Added 2,006.36%
CHRS Coherus Bio Sciences, Inc.	$85.5M	$7.29 Million 0.02% of portfolio	5,283,292	Q4 2024 New
IMNM Immunome Inc.	$120M	$7.07 Million 0.02% of portfolio	688,790	Q4 2024 Added 46.35%
TERN Terns Pharmaceuticals, Inc.	$158M	$6.99 Million 0.02% of portfolio	1,251,841	Q4 2024 Reduced 53.76%
ARDX Ardelyx, Inc.	$983M	$6.9 Million 0.02% of portfolio	1,333,810	Q4 2024 New
LXRX Lexicon Pharmaceuticals, Inc.	$140M	$6.65 Million 0.02% of portfolio	8,988,421	Q4 2024 Added 630.74%
RLAY Relay Therapeutics, Inc.	$492M	$6.56 Million 0.02% of portfolio	1,592,753	Q4 2024 Added 18.03%
EYPT Eye Point Pharmaceuticals, Inc.	$220M	$6.39 Million 0.02% of portfolio	857,853	Q4 2024 Added 90.08%

Shares Options

Steven Cohen

Steven Cohen is the founder and CEO of Point72 Asset Management, a successful investment firm that uses technology and data-driven approaches to investing. Cohen is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.

Track Steven Cohen's portfolio

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account